9 Facts About Lichen Sclerosus and Why Menopause Increases Your Risk
The number of women who describe being told 'it's just dryness, use a moisturiser' — when what they actually had was lichen sclerosus — is genuinely heartbreaking. This is a condition that responds well to treatment when caught early, but causes irreversible changes when it isn't. If something feels wrong with your vulvar skin and the standard advice isn't helping, please push for a proper look.
Learn more about Rose →Lichen Sclerosus Is a Chronic Inflammatory Skin Condition, Not an Infection
Lichen sclerosus (LS) is a long-term inflammatory dermatological condition that primarily affects the skin of the vulva and perianal area, though it can occur elsewhere on the body. It causes the skin to become thin, white, and fragile — often described as tissue-paper-like — and can produce intense itching, burning, and pain during sex or urination. It is not caused by bacteria, fungi, or a sexually transmitted infection, which means antifungal creams and antibiotics will not resolve it.
It Is Far More Common in Postmenopausal Women Than Most People Realise
Population studies suggest lichen sclerosus affects roughly 1 in 70 to 1 in 30 women, with the highest incidence occurring after menopause — particularly in the decade following the final period. The condition has a bimodal distribution, meaning it also appears in prepubertal girls, which strongly suggests hormonal environment plays a central role in vulnerability. Despite these numbers, many healthcare providers do not routinely screen for it during menopause consultations.
Falling Oestrogen Appears to Create the Conditions for LS to Develop or Worsen
The vulvar skin is richly supplied with oestrogen receptors, and the decline in oestrogen at menopause leads to thinning, reduced elasticity, and changes in local immune regulation — all of which may lower the threshold for lichen sclerosus to emerge or flare. Research has not yet established that low oestrogen directly causes LS, but the strong correlation with postmenopausal status and prepubertal hormonal states points firmly in that direction. This is one reason why LS and genitourinary syndrome of menopause (GSM) often coexist and complicate each other's diagnosis.
Lichen Sclerosus Is Frequently Confused With Vaginal Atrophy — and That Confusion Causes Harm
Both conditions cause vulvar dryness, itching, painful sex, and discomfort, which is why LS is routinely misidentified as GSM or general vaginal atrophy and treated with moisturisers alone. The critical difference is that LS involves visible skin changes — whitening, architectural distortion, fissuring, and fragility — that require a clinical examination to identify, not just a symptom checklist. Women who are treated for atrophy without improvement should specifically ask whether lichen sclerosus has been considered and whether a dermatological or vulvology review is appropriate.
The Condition Has an Autoimmune Component That Menopause May Amplify
Strong evidence supports an autoimmune basis for lichen sclerosus: studies consistently find elevated rates of thyroid disease, vitiligo, alopecia areata, and other autoimmune conditions in women with LS, and autoantibodies to extracellular matrix proteins have been detected in affected tissue. Menopause is also associated with shifts in immune regulation, which may help explain why existing but subclinical LS sometimes becomes symptomatic after the hormonal transition. Women with a personal or family history of autoimmune conditions are considered higher risk.
Untreated LS Can Lead to Permanent Anatomical Changes
Without appropriate treatment, lichen sclerosus causes progressive scarring that can narrow the vaginal opening, cause the inner labia to fuse or disappear, and bury the clitoris under thickened tissue — changes that cannot be fully reversed. These architectural changes make sex physically impossible for some women and can severely impair urinary function. This is why early and consistent treatment is considered essential, not optional — the condition does not typically resolve on its own.
The First-Line Treatment Is a High-Potency Topical Corticosteroid — and It Works
Ultrapotent topical corticosteroids, most commonly clobetasol propionate, are the established first-line treatment for lichen sclerosus and have strong evidence supporting their ability to control symptoms, halt progression, and in some cases partially reverse early skin changes. Treatment is typically applied daily for several weeks, then tapered to a maintenance dose used several times a week long-term. Many women are initially resistant to the idea of using a strong steroid on delicate tissue, but evidence consistently shows the risks of undertreating LS far outweigh the risks of correctly supervised steroid use.
Local Oestrogen and HRT Do Not Treat LS — But They Can Help Manage Coexisting Symptoms
Topical oestrogen and systemic hormone replacement therapy address the atrophic changes of GSM but do not treat the inflammatory and autoimmune processes driving lichen sclerosus. However, because LS and GSM so frequently coexist, using local oestrogen alongside a corticosteroid regimen can help restore tissue health, reduce fragility, and improve overall comfort. Clinicians experienced in vulvar conditions will often recommend both treatments in parallel when both conditions are present.
Women With Lichen Sclerosus Have a Small But Real Increased Risk of Vulvar Cancer
Long-term, inadequately treated lichen sclerosus is associated with an approximately 3–5% lifetime risk of developing vulvar squamous cell carcinoma — a risk substantially higher than the general population but one that consistent treatment and monitoring can significantly reduce. Any new ulceration, thickening, or areas that fail to respond to treatment should be assessed promptly, as these can be early warning signs that warrant a biopsy. Regular vulvoscopy or review by a vulval specialist is recommended for women with confirmed LS, typically annually once the condition is stable.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.